Outlook Therapeutics is trading 5.55% up at $0.59 in pre-market on October 23, 2026, with no company-specific catalyst identified.
- The latest listed company press release was October 9, announcing a commercial chief appointment.
- Available evidence does not establish a broader-market catalyst for the gain.
- The stock has also risen over recent sessions, but that trend alone does not explain the pre-market move.